www.yypharm.org

Yao Yuan
—Academy for Pharma Innovation

Presents

The 5th Yao Yuan Biotech-Pharma Symposium

Transforming Pharmaceutical R & D

Illinois Science & Technology Park, 8045 Lamon Avenue , Skokie, IL60077

May 18, 2013

Innovation

Partnership

Globalization

PURIFLASH® MS

Mass Directed Purification

Normal Phase
Reverse Phase

XIC & TIC Collection
APCI or ESI Ion Source

Prep HPLC
Flash

Purification Based Software

Change any parameter at any time

Sample Loading

Prep HPLC 5mg - 10g / Flash 10mg - 160g

Column Sizes

Prep HPLC 10mm - 75mm ID / Flash 4g - 1250g

Dimensions: PuriFlash 4250-250 (WxDxH): 18.9 x 17.5 x 34 / PuriFlash MS: 11 x 22 x 31“

interchim®

www.interchiminc.com Tel: 800.562.8262

TO ATTENDANTS

The pharmaceutical industry has experienced tremendous challenges in recently years due to “patent cliff” threats as well as changes in public and healthcare policies pertaining to how medicine is accessed and paid for. These challenges have caused investors, industrial leaders and scientists to question return on investment, justification of capital spending and career sustainability in R&D. With a theme of “Transforming Pharmaceutical R&D”, Yao Yuan’s 5th Biotech-Pharma Symposium seeks to gather and inspire scientists at the forefront of discovery and development in the pharmaceutical and biotechnology industries and to provide some context in this period of transition. This event will be a valuable opportunity for learning amongst professionals, academicians and students, and serves as a platform for discussions around transforming pharmaceutical R&D. Though primarily intended to be a Midwest regional gathering, e.g., Illinois, Indiana, Iowa and Wisconsin, the Symposium has historically attracted attendees from all areas of the country. We welcome your participation, and look forward to an exciting symposium.

Ze-Qi Xu, Ph.D, President of SynChem GMP

Chair of the Organizing Committee
The 5th Yao Yuan Biotech-Pharma Symposium

ACKNOWLEDGEMENT

Takeda
GRACE
Enriching Lives, Everywhere.™
Ark Pharm
interchim®
SynChem
GILSON®
Chemglass Life Sciences

ORGANIZING COMMITTEE

of the 5th Yao Yuan Biotech-Pharma Symposium

Ark Pharm, Inc.
Libertyville, IL USA

About Us

Ark Pharm, Inc. specializes in design and synthesis of medicinal building blocks, scaffolds and other advanced intermediates serving drug descovery research.

Our Services

- Medicinal Building Blocks and Scaffolds
- Advanced Intermediates
- Custom Synthesis and Contract Research
- Process Research and Scale-up

Shanghai R&D

- 31,500 square ft wet chemistry laboratory
- > 150 employees
- > 10,000 products in stock

QA&QC

- ISO 9001:2008 Certified

Contact Us

Ark Pharm, Inc.
1840 Industrial Drive, Suite 280
Libertyville, IL 60048 USA
Phone:847-367-3680
Fax: 847-367-3681
E-mail:sales@arkpharminc.com
Website:www.arkpharminc.com

AK-46582 [886372-90-3]



AK-23813 [875781-43-4]



AK-23925 [2435-50-9]



AK-27425 [1053656-57-7]



AK-24442 [324769-06-4]

The 5th Yao Yuan Biotech-Pharma Symposium

Transforming Pharmaceutical R&D

May 18, 2013 (9:00 AM-3:30 PM)

Agenda

8:00 AM — 9:00 AM	Registration
9:00 AM— 9:10 PM	Opening Remark **Ze-Qi Xu**, Ph.D, President, SynChem GMP
9:10 AM — 12:00 AM	**Session One** Moderator: **Thomas von Geldern**, Ph.D, Individual Consultant, Former Research Fellow at Abbott Laboratories
9:10 AM —10:00 AM	**Transform Pharmaceutical R&D, Leveraging Open Innovation & Accessing Global Talents** **Guoxin Zhu**, Ph.D, Group Senior Director, Eli Lilly
10:00 AM —10:50 AM	**Discovery of ABT-333 and ABT-072, Potent Inhibitors of HCV NS5B Polymerase** **John Randolph**, Ph.D, Associate Research Fellow, AbbVie Inc.
10:50 PM—11:10 PM	Coffee Break
11:10 AM—12:00 AM	**Nanomedicine in Oncology** **Wenbin Lin**, Ph.D, Kenan Distinguished Professor of Chemistry and Vice Chair, Department of Chemistry, University of North Carolina, and Professor, Lineberger Comprehensive Cancer Center, UNC
12:00 AM—1:30 PM	**Complementary Lunch**
1:30 - 3:30 AM	**Session Two** Moderator: **Betty Yao**, Ph.D, Associate Director & Volwiler Associate Research Fellow, AbbVie Inc.
1:30 PM—2:20 PM	**Ponatinib, a third generation BCR-ABL inhibitor approved for leukemia treatment and AP26113, a phase 2 trial compound for ALK+ non-small cell lung cancer treatment** **Wei-Sheng Huang**, Ph.D. Associate Director, Ariad
2:20 PM —2:40 PM	Break (soft drink & cookie)
2:40 PM—3:30 PM	**The Discovery of Omecamtiv Mecarbil: the First, Selective, Small Molecule Activator of Cardiac Myosin** **Bradley Morgan**, Ph. D, Vice President, Cytokinetics.
3:30 PM	**Conclusion**

SynChem, Inc.







SynChem Inc.

1400 Chase Ave
Elk Grove Village, IL 60007
Phone: (847) 298-2436
Fax: (847) 298-2439
catalog@synchem.com

SynChem's On-Demand Catalog Product Services



SC-25520



SC-04826



SC-24940



SC-04783



SC-21941



SC-04788



SC-25744



SC-35233



SC-25340



SC-25440



SC-35564



SC-25908



SC-35653

SC-35668



SC-35648

BIOGRAPHICAL SKETCH

Wei-Sheng Huang

Wei-Sheng Huang, Ph.D., is Associate Director of Chemistry, ARIAD Pharmaceuticals, Inc. Since joining ARIAD in 2004 his work has been focused on discovery of kinase inhibitors as anti-cancer agents. He was one of a few major contributors, both mentally and physically, to the discovery of Iclusig (ponatinib, formerly AP24534), an approved (in December 2012) drug for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. Wei-Sheng also played a pivotal role in conceiving AP26113, an ALK inhibitor for the treatment of non-small cell lung cancer presently under phase 2 clinical trial. From 2001 to 2004, Wei-Sheng was a medicinal chemist at UCB Research/UCB Pharma (Cambridge, MA) where he worked on several projects in the area of inflammation and respiratory disease. Wei-Sheng received a B.S. from Huazhong University of Science and Technology (Wuhan, China) and a Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Science. He completed his postdoctoral trainings at University of Virginia and then at Massachusetts Institute of Technology. Dr. Huang co-authored over 40 publications in peer-reviewed journals and was co-inventor of 5 issued US patents and 6 pending patent applications. He regularly reviews manuscripts for J Med Chem, J Org Chem, ACS Med Chem Lett, Bioorg Med Chem, ChemMedChem, MedChemComm, and Future Med Chem.

Wenbin Lin

Dr. Wenbin Lin is the Kenan Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill (UNC-CH). He is also a joint professor at Division of Molecular Pharmaceutics (School of Pharmacy) and Lineberger Comprehensive Cancer Center at UNC-CH. Dr. Lin will start his new career as Professor of Chemistry at the University of Chicago on July 1, 2013. He obtained a BS degree from the University of Science and Technology (Hefei, China) in 1988 and received a PhD degree in chemistry from the University of Illinois at Urbana -Champaign in 1994. He was a NSF postdoctoral fellow at Northwestern University before becoming an assistant professor of chemistry at Brandeis University in 1997. He moved to the University of North Carolina in 2001, where he quickly moved through the ranks and became the Kenan Distinguished Professor in 2011. Dr. Lin's research efforts focus on designing molecular materials for sustainability and human health. His group has worked on a variety of research areas, including nonlinear optical materials, porous materials for catalysis and separation, solar fuels, and nanomedicine. Dr. Lin's group has published over 200 peer-reviewed papers, and his work has been well received by the community as evidenced by his selection to be among the top 10 chemists in the 1999-2009 decade based on per article citations. Dr. Lin has won numerous professional honors for his contributions to the rational design of functional molecular materials.

Bradley P. Morgan

Bradley P. Morgan, PhD / Vice President, Drug Discovery & Early Development / Cytokinetics Inc.

Brad Morgan has been with Cytokinetics since 2002 and is currently the Vice President, Drug Discovery & Early Development where he is responsible for groups in Medicinal & Process Chemistry, Analytical Chemistry, ADME/DMPK, Pharmaceutical Sciences, and Non-Clinical Development with the primary focus of drug discovery and development in cardiovascular and muscle biology related diseases. During his tenure at Cytokinetics, small molecule clinical candidates with novel mechanisms of action have been discovered with the potential to treat heart failure, cancer, asthma, COPD, and diseases of muscle weakness. For example, *omecamtiv mecar*

Discover More...

with the Reveleris® Flash Chromatography System.

GRACE
Davison

Recover More with RevealX™ Detection Technology

- Simultaneous UV and ELSD detection
- More compounds from complex mixtures
- Multiple purifications in one step

Purify More with Reveleris® Flash Cartridges

- 3 times higher recovery
- Higher loading capacity
- Superior resolution

Discover More with Navigator™ Software

- Deliver faster results with higher purity
- Fast, simple method optimization
- Run times reduced by up to 30%

Discover More

www.discoverysciences.com

Grace Davison Discovery Sciences

BIOGRAPHICAL SKETCH

bil (formerly CK-1827452) is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction. In collaboration with Amgen, it is being evaluated in Phase II clinical studies as a potential treatment of heart failure in both intravenous and oral formulations with the goal of establishing a new continuum of care for patients in both the in-hospital and outpatient settings. Additionally, *tirasemtiv* (formerly CK-2017357) is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company's skeletal muscle contractility program. *Tirasemtiv* selectively activates the fast skeletal muscle troponin complex and increases its sensitivity to calcium, resulting in increased skeletal muscle force. *Tirasemtiv* is currently in Phase II clinical trials for the treatment of ALS.

Prior to joining Cytokinetics (1993-2002), Brad served in a variety of positions at Pfizer Global Research and Development in Groton, Connecticut including the role of Group Leader, Chemistry for Cardiovascular and Metabolic Diseases. He led discovery programs that placed selective, nuclear receptor modulator drug candidates and selective G-coupled protein receptor antagonist drug candidates into development for obesity.

Brad received his B.S. degree in Chemistry from Illinois State University (magna cum laude), a Ph.D. from the University of California at Berkeley, and Post-Doctoral studies at the California Institute of Technology.

John T. Randolph

John Randolph has more than 20 years of experience in drug discovery, including over 18 years with Abbott's Global Pharmaceutical Research and Development organization. His work at Abbott has been largely focused in the area of antiviral research, where he has contributed to the discovery of promising drug candidates for the treatment of HIV and HCV infection. Dr. Randolph was part of the medicinal chemistry team that discovered ABT-072 and ABT-333, two inhibitors of HCV NS5B polymerase, and ABT-267, an inhibitor of HCV NS5A. These compounds are currently undergoing clinical studies aimed at identifying effective drug combinations for treating HCV infection. In addition to his experience in infectious disease research, Dr. Randolph has worked on projects at Abbott aimed at identifying novel treatments for prostate cancer as well as new agents for the treatment of pain. His research has resulted in over 50 patents and scientific publications, including presentations at major conferences. In recognition of his important contributions to Abbott Research, Dr. Randolph was inducted into Abbott's Volwiler Society in 2009.

Dr. Randolph received his Ph.D. in 1992 from the University of Alabama, where he worked on the synthesis of diphosphonate nucleotide glycosyl transferase inhibitors under the direction of Professor David C. Baker. He went on to do postdoctoral research as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor Samuel J. Danishefsky at Yale University and Memorial Sloan Kettering Cancer Center in New York. There he contributed to early group efforts to synthesize complex tumor-associated glycoconjugates through glycal assembly. Dr. Randolph joined Abbott in 1994.

Guoxin Zhu

Dr. Guoxin Zhu, Group Senior Director of Lilly Research Laboratories, is currently leading the medicinal chemistry group at Lilly Discovery Chemistry Research and Technology Division. As a member of Discovery Chemistry senior management, he is responsible for small molecule medchem strategy and portfolio delivery from project initiation to clinical candidate selection in all disease areas at Lilly.

From August 2005 to August 2007, Dr. Zhu took the corporate international assignment in China leading the Lilly China Research activities, including the strategic partnership with Shanghai ChemExplorer, which is an exclusive contract research organization for Lilly since 2002. He has aided in positioning Lilly to capitalize on the evolving landscape of scientific capabilities/capacities in Asia through actively exploring & evaluating scientific and business collaborators including academic institutes in China.

Dr. Zhu earned his bachelor degree from Hangzhou University in 1990 and doctorate degree in organic chemistry from Shanghai Institute of Organic Chemistry, the Chinese Academy of Sciences in 1995. He joined the Lilly Research Laboratories in 1998 after his postdoctoral research at the Pennsylvania State University. He was a key scientific contributor for multiple projects in the area of metabolic disease, diabetes and oncology; he is the key inventor for a clinical compound that just completes phase 2 studies. He is a coauthor of over 40 scientific publications and co-inventor of more than 30 patents and patent applications before he took on administrative role in 2005. He is a member of the American Chemical Society, Chinese Pharmaceutical Association, the American Diabetes Association and BayHelix Group.

The 6th Yao Yuan Biotech-Pharma Symposium

Industry-Connect: Turning Discoveries into Pharmaceutical Innovations

October 26, 2013
Northwestern University
Tech Building 2145 Sheridan Road, Evanston, IL 60208

Sponsored by Yao Yuan—Academy for Pharma Innovation, the 6th Yao Yuan Biotech-Pharma Symposium, with a theme of "Industry-Connect: Turning Discoveries into Pharmaceutical Innovation", attempts to serve as a platform for productive interactions between academic and industrial researchers. While the Morning Session of the conference focuses on current technologies for pharmaceutical discovery as well as discussions on career opportunities, particularly for chemistry and biology majors, the Afternoon Session features a "SynChem Award Poster Session". All poster presentations submitted before September 30, 2013 will be reviewed by a team of outstanding experts in the field. One 1st, two 2nd and three 3rd place award winners will be selected, and the top three candidates will be invited to give oral presentations.

Tentative agenda:

- ◊ Plenary seminars on current technologies of pharmaceutical R & D
- ◊ Discussions on career opportunities and development for students majoring in chemistry and biology
- ◊ "SynChem Poster Award" selected by outstanding experts in the field
- ◊ Oral presentations delivered by award winning poster authors

www.yypharm.org

Yao Yuan & Sichuan University
present

The 8th Yao Yuan
Biotech/Pharma International Symposium

From Personalized Medicine to Immunology
A Model for Future Pharma Innovation

Chengdu, China
November 10-14, 2014

Co-sponsored by Yao Yuan—Academy for Pharma Innovation and Sichuan University, Yao Yuan's 8th Biotech-Pharma International Symposium will be held on November 10-14 in Chengdu, China. The theme of the conference is chosen to be "From Personalized Medicine to Immunology, A Model for Future Pharma Innovation" to highlight our goal in exploring a healthy, innovative, and rejuvenated model for future avenues of biotech and pharmaceutical development. This particular symposium tempts to diagnose the decline in current pharmaceutical R&D efficiency, emphasize the latest but successful pharmaceutical development, and propose feasible and effective solutions to the challenging environment facing pharmaceutical industry. Personalized medicine and immunology are among the main focus of the future pharmaceutical developments. We look forward to another exciting conference and seeing you all in Changsha, China.

Featured Speakers

Bruce A. Beutler, Ph.D, Regental Professor, Raymond and Ellen Willie Distinguished Chair in Cancer Research, Director, Center for the Genetics of Host Defense, UT Southwestern Medical Center
Michael A. Marletta, Ph.D, President, Scripps Research Institute
Yuquan Wei, Ph.D, Academician, Chinese Academia of Science; Vice President & Professor, Sichuan University
Lewis Cantley, Ph.D, Professor of Cell Biology, Harvard Medical School
Richard A. Cerione, Goldwin Smith Professor, Cornell University
Bob Humphries, Director, VisionRealisation, Ex-Vice President, Astra-Zeneca
Changgong Liu, Ph.D, Professor, MD Anderson Cancer Center
Songlin Xue, Ph.D, Sr. Vice President, Takeda Global Research & Development
Youssef L. Bennani, Ph.D, Vice President, Vertex Pharmaceutical
Wenqing Yao, Ph.D, Sr. Vice President, Incyte Pharmaceutical
Jef De Brabander, Ph.D, Julie and Louis Beecherl Jr. Chair in Medical Science, UT Southwestern Medical Center
Peter Senter, Ph.D, Vice President, Seattle Genetics
Yang-Xin Fu, Ph.D, Professor of Pathology, The University of Chicago

YAO YUAN

药源

ACADEMY FOR PHARMA INNOVATION

BRIDGE

Bridge American and Chinese bio-pharmaceutical industries

- Create collaborative business opportunities for biopharmaceutical companies from China and the US
- Connect capital and biopharmaceutical assets

EDUCATION

Promote cutting edge knowledge and strategies in drug research

- Organize educational lectures, seminars, conferences, workshops, executive briefings, trade missions and networking events.
- Build professional networks and facilitate career development for biopharmaceutical specialists in both the US and China through lectures, mentor program, job listing,.

Report and analyze news in bio-pharmaceutical industry

- Report and analyze daily news, industry trends, and hot programs via **www.yypharm.cn**



www.yypharm.org

Yao Yuan—Academy for Pharma Innovation, is an independent, non-political, and IRS-registered not-for-profit organization